04 Apr Evolution Biotechnologies announces appointment of Dr. Victor Brugman as senior scientist on its house dust mite control project
Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the appointment of Dr. Victor Brugman as senior scientist on its dust mite control project. Dr. Brugman will be working with the ARCTEC unit at the London School of Hygiene and Tropical Medicine in London in the early stages of the work, and will be moving to the company’s central facility at Colworth Science Park later in the year.
Dr. David Harper, Chief Officer of Evolution, said “This is an important step for the company, I would like to welcome Dr. Brugman to the company at this exciting stage of its development. He brings a wealth of experience to the company which will be directly applicable to this project and to our long term aims.”
About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.
About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.